Jiangsu Recbio Technology Co., Ltd. (HKG:2179)

Market Cap	3.95B
Revenue (ttm)	28.74M
Net Income (ttm)	-593.24M
Shares Out	489.37M
EPS (ttm)	-1.24
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	98,500
Average Volume	68,800
Open	7.49
Previous Close	8.08
Day's Range	7.20 - 7.91
52-Week Range	6.76 - 9.80
Beta	-0.22
RSI	50.18
Earnings Date	Aug 20, 2025

About Everbridge

Jiangsu Recbio Technology Co., Ltd., a vaccine company, engages in the research, development, and commercialization of subunit vaccines in the People’s Republic of China. The company is developing vaccines for the treatment of cervical cancer, and anal and genital warts, including REC603, a recombinant human papillomavirus (HPV) 9-valent vaccine that is in phase III clinical trial; REC601 and REC602 recombinant HPV bivalent vaccines targeting HPV type 6/11, which are in phase I clinical trials; REC604a, a recombinant HPV quadrivalent vaccine th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 531
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2179

Financial Performance

In 2024, Jiangsu Recbio Technology's revenue was 27.01 million, a decrease of -11.10% compared to the previous year's 30.38 million. Losses were -557.46 million, -2.53% less than in 2023.